Showing results (1261-1270 of 1,303) with videos related to
Sort By:
Pageof 131
Journal of the American Academy of Dermatology|February 28, 2004
A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgarisJames Leyden, Wilma Bergfeld, Lynn Drake, et al.The Journal of Clinical Investigation|March 13, 2020
Inherited human IFN-γ deficiency underlies mycobacterial diseaseGaspard Kerner, Jérémie Rosain, Antoine Guérin, et al.The Lancet. Healthy Longevity|October 23, 2025
Remote, lower-intensity, multidomain lifestyle intervention for subjective cognitive decline or mild cognitive impairment (APPLE-Tree): a multicentre, single-masked, randomised controlled trialHarriet Demnitz-King, Mariam Adeleke, Julie A Barber, et al.Science Immunology|December 1, 2019
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-βJuan Li, Marco Ritelli, Cindy S Ma, et al.The Journal of Experimental Medicine|June 17, 2021
Human STAT3 variants underlie autosomal dominant hyper-IgE syndrome by negative dominanceTakaki Asano, Joëlle Khourieh, Peng Zhang, et al.Nature Medicine|June 21, 2016
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemiaSheng Li, Francine E Garrett-Bakelman, Stephen S Chung, et al.Blood Neoplasia|January 29, 2026
The LMO2-LDB1-TAL1 complex regulates transcription networks in acute myeloid leukemiaNicholas Dunham, Zhenjia Wang, Yaseswini Neelamraju, et al.Nature|November 1, 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y Saiki, et al.Cancer Cell|July 16, 2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative NeoplasmsSara C Meyer, Matthew D Keller, Sophia Chiu, et al.Nature|July 11, 2003
Large changes in Pluto's atmosphere as revealed by recent stellar occultationsB Sicardy, T Widemann, E Lellouch, et al.Pageof 131